Immunotherapy to treat cancer has been around for a while, but new research is making headway in directions that are both exciting and are giving hope to patients fighting cancer. In this video, Dr Shubham Pant, an oncologist in Houston Texas, demystifies immunotherapy.
Dr. Kuzel discusses treatment options for metastatic RCC based on risk stratification. In the article, Dr. Kuzel talks about two different case scenarios.
Isaac Chan, a medical oncology fellow at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses a patient's right to refuse palliative care.
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Although a subset of clear cell renal cell carcinoma (ccRCC) patients respond to immune checkpoint blockade (ICB), predictors of response remain uncertain.
The newest issue of the journal, “Kidney Cancer” just came out! The issue includes two review articles on the topics of diagnostic imaging and adjuvant therapy, a commentary about partial nephrectomy and five research articles, plus a new Clinical Trials Corner.
An initiative launched today encourages newly-diagnosed African American cancer patients in Maryland to consider clinical trials as the first-line option, not the last resort. The ads are intended to reward those progressive physicians who are actively supporting their patients’ access to the most advanced options for improved care, including clinical trials for prostate, bladder and kidney cancer.
Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma (RCC) that should receive adjuvant sunitinib (Sutent) therapy.
Cancer treatment has been transformed by the use of monoclonal antibodies (mAbs) that block immune inhibitory ligands CTLA-4 and PD-1, known as immune checkpoint inhibitors (CPIs). With these options for treatment of cancers that are resistant to conventional cancer therapies, the life expectancy of patients with melanoma, lung cancer, renal cell carcinoma, and other cancers, has shown significant improvement. However, according to the journal Diabetes, some patients experience adverse effects. One percent of patients treated with anti–PD-1 or –PD-L1 CPIs develop diabetes.
In this video, Dr. Robert J. Motzer discusses the treatment methods he used on a 49-year-old male with recurrent RCC.
The use of next-generation sequencing (NGS) is a novel means of improving cancer care, but there are other methods of improving care that extend beyond the panel itself, explained Leonid Shunyakov, MD, a hematologist/oncologist at Central Care Cancer Center.
|NeonCRM by Neon One|